ATE447617T1 - Verwendung von rekombinanten proteinen in menschlichen zellen - Google Patents

Verwendung von rekombinanten proteinen in menschlichen zellen

Info

Publication number
ATE447617T1
ATE447617T1 AT05100732T AT05100732T ATE447617T1 AT E447617 T1 ATE447617 T1 AT E447617T1 AT 05100732 T AT05100732 T AT 05100732T AT 05100732 T AT05100732 T AT 05100732T AT E447617 T1 ATE447617 T1 AT E447617T1
Authority
AT
Austria
Prior art keywords
recombinant proteins
human
human cells
compositions
proteins
Prior art date
Application number
AT05100732T
Other languages
English (en)
Inventor
Guus Hateboer
Karina Cornelia Verhulst
Govert Schouten
Alphonsus Uytdehaag
Abraham Bout
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE447617(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE447617T1 publication Critical patent/ATE447617T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05100732T 1999-04-15 2000-04-17 Verwendung von rekombinanten proteinen in menschlichen zellen ATE447617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201176 1999-04-15
EP99204434 1999-12-21

Publications (1)

Publication Number Publication Date
ATE447617T1 true ATE447617T1 (de) 2009-11-15

Family

ID=26153302

Family Applications (3)

Application Number Title Priority Date Filing Date
AT00921175T ATE289354T1 (de) 1999-04-15 2000-04-17 Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
AT09174441T ATE536417T1 (de) 1999-04-15 2000-04-17 Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein
AT05100732T ATE447617T1 (de) 1999-04-15 2000-04-17 Verwendung von rekombinanten proteinen in menschlichen zellen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT00921175T ATE289354T1 (de) 1999-04-15 2000-04-17 Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
AT09174441T ATE536417T1 (de) 1999-04-15 2000-04-17 Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein

Country Status (18)

Country Link
EP (3) EP1161548B2 (de)
JP (1) JP4210036B2 (de)
CN (1) CN100457914C (de)
AT (3) ATE289354T1 (de)
AU (1) AU772352B2 (de)
CA (1) CA2370477C (de)
CY (1) CY1109759T1 (de)
DE (2) DE60018171T3 (de)
DK (3) DK1533380T3 (de)
ES (3) ES2335775T3 (de)
HK (1) HK1048138B (de)
IL (2) IL145849A0 (de)
MX (1) MXPA01010360A (de)
NO (1) NO328951B1 (de)
NZ (1) NZ514951A (de)
PT (2) PT1161548E (de)
SI (2) SI1161548T2 (de)
WO (1) WO2000063403A2 (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
WO2003089468A1 (en) * 2002-04-19 2003-10-30 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EA012340B1 (ru) 2001-10-29 2009-10-30 Круселл Холланд Б.В. Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac
DE60224843T2 (de) 2001-12-07 2009-01-08 Crucell Holland B.V. Herstellung von viren, virusisolaten, und impfstoffen
AU2002225509A1 (en) * 2001-12-07 2003-06-17 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
US20050048038A1 (en) 2001-12-17 2005-03-03 Jones David Halford Ashton Efficient production of f(ab')2 fragments in mammalian cells
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
AU2003206251B2 (en) * 2002-01-09 2008-03-13 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
EP1519959B1 (de) 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antikörper und fusionsproteine davon und anwendungsverfahren
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
EP1483294B2 (de) 2002-03-01 2019-10-30 Immunomedics, Inc. Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
KR101143035B1 (ko) 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1523496B1 (de) 2002-07-18 2011-06-29 Merus B.V. Rekombinante Produktion von Antikörpermischungen
US7300655B2 (en) 2002-08-01 2007-11-27 Immunomedics, Inc. Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1623023B1 (de) 2003-05-09 2008-11-12 Crucell Holland B.V. Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
ATE469920T1 (de) * 2003-05-23 2010-06-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
EP2216342B1 (de) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 Antikörper
EP1508576A1 (de) * 2003-08-20 2005-02-23 Crucell Holland B.V. Effiziente Herstellung von IgA in rekombinanten Säugerzellen
NZ545501A (en) 2003-10-02 2010-12-24 Crucell Holland Bv Packaging cells for recombinant adenovirus
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
ES2646560T3 (es) 2004-01-20 2017-12-14 Merus N.V. Mezclas de proteínas de unión
EP2308958A3 (de) 2004-03-05 2011-08-10 DSM IP Assets B.V. Zellkultur mittels kontinuierlicher perfusion und alternierendem tangentialen fluss
BRPI0511479C1 (pt) 2004-05-27 2021-05-25 Crucell Holland Bv molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
AU2005300503B2 (en) 2004-11-08 2010-12-16 Chromagenics B.V. Selection of host cells expressing protein at high levels
AU2005303758B2 (en) 2004-11-11 2011-04-28 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2455100A3 (de) * 2005-11-07 2012-11-07 The Rockefeller University Reagenzien, Verfahren und System zur Auswahl eines zytotoxischen Antikörpers oder einer Variante davon
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
WO2007107578A1 (en) 2006-03-20 2007-09-27 Chromagenics B.V. Expression augmenting dna fragments, use thereof, and methods for finding thereof
NZ572379A (en) * 2006-04-05 2012-06-29 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EA016717B1 (ru) 2006-06-06 2012-07-30 Круселл Холланд Б.В. Моноклональное антитело человека, обладающее опсонизирующей фагоцитарной киллерной активностью в отношении enterococcus и staphylococcus aureus, и его применение
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
HUE028365T2 (en) 2006-07-14 2016-12-28 Dpx Holdings Bv An improved method for cell culture
EP2450378B1 (de) 2006-09-07 2015-11-04 Crucell Holland B.V. Zur Neutralisierung des Influenzavirus H5N1 fähige humane Bindungsmoleküle sowie deren Verwendungen
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP4997253B2 (ja) 2007-08-10 2012-08-08 Ｔｏｔｏ株式会社 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法
ES2450998T3 (es) * 2007-12-13 2014-03-26 F. Hoffmann-La Roche Ag Nuevas variantes de proteína de cubierta E1 de rubéola y su utilización en la detección de anticuerpos anti-rubéola
US20120039939A1 (en) * 2008-04-11 2012-02-16 The Johns Hopkins University Compositions and methods for vaccine and virus production
US7846744B2 (en) 2008-04-22 2010-12-07 Ravetch Jeffrey V Methods of identifying anti-inflammatory compounds
CN102216449B (zh) * 2008-07-15 2013-03-06 克鲁塞尔荷兰公司 用于培养per.c6细胞以及从中生产产物的可规模化的方法
JP6049163B2 (ja) 2008-07-21 2016-12-21 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 改善された治療上の特徴のための抗体の構造変異体
PL2421895T3 (pl) 2009-04-23 2016-04-29 Crucell Holland Bv Rekombinowana ludzka alfa1-antytrypsyna
BRPI1012749B1 (pt) 2009-05-11 2022-01-11 Janssen Vaccines & Prevention B.V. Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica
JP4998814B2 (ja) 2009-10-01 2012-08-15 Ｔｏｔｏ株式会社 Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
MY166282A (en) 2011-07-14 2018-06-25 Crucell Holland Bv Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharmaceuticals Inc Murganhos da cadeia leve universal humanizada
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN102827273A (zh) * 2012-02-16 2012-12-19 张小莺 抗痘苗病毒IgY抗体的制备
NZ628382A (en) 2012-03-08 2017-03-31 Janssen Vaccines & Prevention Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
NZ799532A (en) 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
US9657290B2 (en) * 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
EP2869845B1 (de) 2012-07-06 2019-08-28 Genmab B.V. Dimerprotein mit dreifacher mutation
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
EP2900692A1 (de) 2012-09-27 2015-08-05 Crucell Holland B.V. Humane bindungsmoleküle mit fähigkeit zur bindung an und neutralisierung von hepatitis-b-viren sowie verwendungen davon
WO2014170258A1 (en) 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g proteins
CA2908878C (en) 2013-04-15 2021-06-29 Crucell Holland B.V. Human antibodies binding to rsv g protein
WO2015000856A1 (de) 2013-07-01 2015-01-08 Charité - Universitätsmedizin Berlin Immortalisierte humane chorionzelllinie sowie verfahren zur immortalisierung humaner chorionzellen
CN104693308B (zh) * 2013-12-05 2020-08-04 同济大学 感受胞内pH变化的Smad5蛋白及其应用
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
JP6772157B2 (ja) 2015-02-05 2020-10-21 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザヘマグルチニンに対する結合分子及びその使用
WO2016124682A1 (en) 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
US10526600B2 (en) 2015-02-22 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Micro-screening apparatus, process, and products
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EA201890028A1 (ru) 2015-07-10 2018-08-31 Мерус Н.В. Антитело, связывающее cd3 человека
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
EP4434632A1 (de) 2016-11-14 2024-09-25 Orca Biosystems, Inc. Verfahren und vorrichtungen zum sortieren von zielpartikeln
KR20190133191A (ko) 2017-03-28 2019-12-02 얀센 백신스 앤드 프리벤션 비.브이. 타우에 특이적으로 결합하는 결합 분자
CA3058343A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
EP3612648A1 (de) 2017-04-18 2020-02-26 Université Libre de Bruxelles Biomarker und targets für proliferative erkrankungen
AU2018312816B2 (en) 2017-08-09 2021-05-27 Merus N.V. Antibodies that bind EGFR and cMET
JP7230819B2 (ja) 2017-10-06 2023-03-01 小野薬品工業株式会社 二重特異性抗体
SG11202004904XA (en) 2017-12-04 2020-06-29 Janssen Vaccines & Prevention Bv Binding molecules that specifically bind to tau
JP2021512602A (ja) 2018-02-01 2021-05-20 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウに特異的に結合する結合分子
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Ｗｎｔシグナル伝達アゴニスト分子
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
TW202118790A (zh) 2019-07-30 2021-05-16 日商小野藥品工業股份有限公司 雙特異性抗體
JPWO2021025140A1 (de) 2019-08-08 2021-02-11
AU2022288080A1 (en) * 2021-06-11 2023-12-07 Monsanto Technology Llc Methods and compositions for altering protein accumulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
GB8900483D0 (en) * 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
DE69125292T2 (de) * 1991-08-01 1997-09-25 Fond Nat Transfusion Sanguine Expression in nicht-tumorbildenden menschlichen Lymphoblasten Zellinien mit einem integrierenden Vektor
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US5610043A (en) * 1994-04-28 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
DK0833934T4 (da) * 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi

Also Published As

Publication number Publication date
EP2163640B1 (de) 2011-12-07
ES2237420T3 (es) 2005-08-01
MXPA01010360A (es) 2004-04-05
DE60018171D1 (de) 2005-03-24
AU772352B2 (en) 2004-04-22
DE60043273D1 (de) 2009-12-17
CY1109759T1 (el) 2014-09-10
IL145849A0 (en) 2002-07-25
HK1048138B (zh) 2009-06-12
WO2000063403A2 (en) 2000-10-26
EP1161548A2 (de) 2001-12-12
ES2335775T3 (es) 2010-04-05
DK1161548T4 (da) 2010-03-01
SI1161548T2 (sl) 2010-02-26
EP1533380A2 (de) 2005-05-25
CN1360638A (zh) 2002-07-24
EP1533380B1 (de) 2009-11-04
DE60018171T2 (de) 2005-12-29
CA2370477C (en) 2010-06-29
DK1161548T3 (da) 2005-05-23
PT1161548E (pt) 2005-06-30
NO20014977L (no) 2001-12-17
NZ514951A (en) 2004-02-27
EP1533380A3 (de) 2005-06-22
ATE536417T1 (de) 2011-12-15
ES2378272T3 (es) 2012-04-10
SI1533380T1 (sl) 2010-03-31
EP2163640A1 (de) 2010-03-17
NO20014977D0 (no) 2001-10-12
WO2000063403A3 (en) 2001-02-15
JP4210036B2 (ja) 2009-01-14
DK1533380T3 (da) 2010-02-01
ES2237420T5 (es) 2010-03-03
DE60018171T3 (de) 2010-05-20
AU4152000A (en) 2000-11-02
DK2163640T3 (da) 2012-03-05
CN100457914C (zh) 2009-02-04
SI1161548T1 (en) 2005-08-31
CA2370477A1 (en) 2000-10-26
HK1048138A1 (en) 2003-03-21
ATE289354T1 (de) 2005-03-15
JP2002541854A (ja) 2002-12-10
EP1161548B2 (de) 2009-10-14
EP1161548B1 (de) 2005-02-16
IL145849A (en) 2009-07-20
NO328951B1 (no) 2010-06-28
PT1533380E (pt) 2010-02-09

Similar Documents

Publication Publication Date Title
ATE447617T1 (de) Verwendung von rekombinanten proteinen in menschlichen zellen
BRPI0417916A (pt) proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
CY1108571T1 (el) Διεργασια για την παραγωγη και τον καθαρισμο ερυθροποιητινης
ES2105442T3 (es) Analogos de eritropoyetina con sitios adicionales de glicosilacion.
DK0851868T3 (da) Höjniveau-ekspression af proteiner
DE60120356D1 (de) Verbesserte galactosylierung von rekombinanten proteinen
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
PT1969007E (pt) Composições e métodos para a produção de uma composição
EA200400605A1 (ru) Способы и средства получения белков с заранее заданными посттрансляционными модификациями
ATE278024T1 (de) Methode zur herstellung von rekombinanten zellen
ATE287945T1 (de) Herstellung und verwendung von dendritischen zellen
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
CY1109167T1 (el) Μεθοδος για την παρασκευη αυξητικης ορμονης και ανταγωνιστη αυτης εχοντας χαμηλοτερα επιπεδα ισομορφικων προσμειξεων αυτου
PT902085E (pt) Eritropoietina humana recombinante com perfil de glicosilacao vantajoso
WO2008041014A3 (en) Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
ATE414762T1 (de) Herstellung kultivierter menschlicher mastzellen und basophilen zur hochdurchsatz-entdeckung kleiner arzneistoffmoleküle
DE60319114D1 (en) Glycosylierte humane interferon alpha isoform
KR930008148A (ko) 변이 인간 프로우로키나아제
KR960023061A (ko) 재조합 인간 적혈구생성 촉진인자의 제조방법, 이를 위한 벡터 및 동물 세포주
BR0206638B1 (pt) processo de regulação de uma célula de eletrólise
SE9901115D0 (sv) Nucleotide sequences

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1533380

Country of ref document: EP